Sun, J., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J., Li, Z., Kim, S., Cho, B. C., Mansoor, W., Li, S., Sunpaweravong, P., Maqueda, M. A., Goekkurt, E., Hara, H., Antunes, L., Fountzilas, C., Tsuji, A., Oliden, V. C., Liu, Q., Shah, S., Bhagia, P., Kato, K., & , (2021). pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, 398(10302), 759–771. http://access.bl.uk/ark:/81055/vdc_100144512720.0x000047